Biological and clinical evidence have showed that combination of ribociclib with MEK inhibitors as binimetinib or trametinib have increased anti-tumoral activity in neoplasias harboring NRAS mutations, including melanoma, NSCLC and colorectal carcinomas in preclinical models in vitro an in vivo [111–113]. The gene discussed is NRAS; the disease is melanoma.